|
PANK3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.77390002476363E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.33100197530212E-11 |
| Normal-vs-Stage2 |
1.54982999999165E-05 |
| Normal-vs-Stage3 |
1.73340009013145E-10 |
| Normal-vs-Stage4 |
2.2649000008812E-08 |
| Stage1-vs-Stage2 |
6.403400E-01 |
| Stage1-vs-Stage3 |
3.375000E-01 |
| Stage1-vs-Stage4 |
4.446000E-01 |
| Stage2-vs-Stage3 |
2.810400E-01 |
| Stage2-vs-Stage4 |
3.069000E-01 |
| Stage3-vs-Stage4 |
9.804800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.2241765640938E-12 |
| Normal-vs-AfricanAmerican |
8.406200E-04 |
| Normal-vs-Asian |
1.3650000019183E-09 |
| Caucasian-vs-AfricanAmerican |
5.245000E-01 |
| Caucasian-vs-Asian |
1.020030E-01 |
| AfricanAmerican-vs-Asian |
8.505600E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.618099650055E-10 |
| Normal-vs-Female |
1.04070085882313E-11 |
| Male-vs-Female |
1.142800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.98570004883436E-09 |
| Normal-vs-Age(41-60Yrs) |
1.23389998218926E-09 |
| Normal-vs-Age(61-80Yrs) |
5.50719999603544E-08 |
| Normal-vs-Age(81-100Yrs) |
2.822300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.493350E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.058400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.362600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.798800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.912400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.175200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.127750E-01 |
| Classical-VS-Follicular |
7.240000E-01 |
| Classical-VS-Other |
1.786630E-01 |
| Classical-VS-Normal |
7.07739999938894E-08 |
| Tall-VS-Follicular |
2.169800E-01 |
| Tall-VS-Other |
5.234200E-01 |
| Tall-VS-Normal |
1.23510000005211E-08 |
| Follicular-VS-Other |
2.396000E-01 |
| Follicular-VS-Normal |
3.65569999827287E-08 |
| Other-VS-Normal |
4.93319999994579E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.28883578756722E-12 |
| Normal-vs-N1 |
6.51089999692545E-08 |
| N0-vs-N1 |
6.025800E-01 |
|
|
